| Teva Pharmaceutical Industries | $1,380 million | Sale of Remaining Assets in Specialty Global Women’s Health Portfolio | CVC Capital Partners Fund VI & Foundation Consumer Healthcare | Acquisition | Israel |
| NeoTract | $1,100 million | NeoTract will greatly enhance Teleflex’s presence in the urological market as NeoTract’s UroLift® System is a novel solution used to address a significant medical issue and targets a total addressable market estimated at over $30 billion. | Teleflex Inc | Acquisition | United States |
| Teva Pharmaceutical Industries | $1,100 million | PARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health business | CooperSurgical | Acquisition | Israel |
| Cook Pharmica | $950 million | Development and manufacturing facility | Catalent | Acquisition | United States |
| Argon Medical Devices Inc | $850 million | Agreement for medical-device company | Shandong Weigao Group Medical Polymer Co | Acquisition | United States |
| AstraZeneca | $766 million | Buy the remaining rights to its anesthetic medicines in markets outside the US | Aspen Global Incorporated | Commercialization Rights | United Kingdom |
| Rigontec | $603 million | Pioneering therapeutic access to the retinoic acid-inducible gene I (RIG-I) pathway | Merck & Co. | Acquisition | United Kingdom |
| Bicycle Therapeutics | $424 million | Discovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease. | Bioverativ | Collaboration | United States |
| Arcus Bioscience | $310 million | For the potential development & commercialization of product candidates in Arcus’s portfolio in Japan and certain other territories in Asia (excluding China) | Taiho Pharma | License Agreement | United States |
| Deciphera Pharmaceuticals, Nightstar Therapeutics and NuCana | $303 million | Focusing on cancer and eye diseases | Undisclosed | IPO Funding | United States |
| Gubra | $300 million | For the development of novel peptide compounds to treat obesity | Boehringer Ingelheim | Collaboration & License Agreement | Denmark |
| Therapure Biopharma Inc | $290 million | To acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market. | 3SBio Inc. | Acquisition | Canada |
| Lightstone Ventures | $250 million | To focus on early-stage therapeutic opportunities across the life sciences sector | Undisclosed | Fund Raising | United States |
| Quantum Pharma | $196.4 million | Unlicensed to licensed UL2L capabilities | Clinigen Group | Acquisition | United Kingdom |
| Presage Biosciences | $183.9 million | For Voruciclib, An Oral, Selective CDK Inhibitor | MEI Pharma | License Agreement | United States |
| BridgeBio Pharma | $135 million | Novel treatments for genetic diseases | Viking Global Investors & KKR | Investment | United States |
| Halozyme Therapeutics, Inc | $105 million | ENHANZE Technology | Bristol-Myers Squibb | License Agreement | United States |
| SpringWorks Therapeutics | $103 million | To developing innovative potential new treatments for underserved patient communities | Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer & LifeArc | Series A Financing | United States |
| Fred Hutchinson Cancer Research | $94.5 million | Next-gen CAR-T for lymphoma/Expansion of CAR T Pipeline into CD20-Directed Immunotherapies | Mustang Bio | License Agreement | United States |
| Gritstone Oncology | $92.7 million | Proceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of Personalized Cancer Immunotherapies | Lilly Asia Ventures, Google Ventures, Trinitas Capital (Beijing) and Alexandria Venture Investments | Series B Financing | United States |
| Autolus | $80 million | Proceeds will be used to establish clinical proof of concept for three novel haematological cancer programs | Syncona, Woodford & Arix Bioscience | Financing | United Kingdom |
| MicroMass Communications | $75.8 million | Micromass is a healthcare marketing agency specializing in digital, relationship marketing, and non-personal promotion. Our unique expertise in human health behavior allows us to create highly effective solutions for patients and health care providers. | UDG Healthcare | Acquisition | United States |
| Aptevo Therapeutics | $74.5 million | To Sell three of its marketed products (WinRho® SDF, HepaGam B®, and VARIZIG®) | Saol Therapeutics | Purchage Agreement | United States |
| Tempus | $70 million | Focused on using genomic sequencing to help doctors customize cancer treatments | Revolution Growth and New Enterprise Associates | Series C Financing | United States |
| LifeMine Therapeutics | $55 million | The company has hacked a code of biologic function hidden in biosynthetic genes that enables the rapid discovery of drugs for previously untargetable disease drivers. | WuXi Healthcare Ventures | Series A Financing | United States |
| Replimune Group | $55 million | To generate clinical proof-of-concept data on its lead oncolytic immunotherapy. | Foresite Capital | Series B Financing | United States |
| Integra LifeSciences | $48 million | Neurosurgery Assets - Camino ICP monitoring product line and associated products | Natus Medical | Acquisition | United States |
| Shanghai SinoMedCare Biotech | $40 million | The Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments. | Fosun Pharma | Stake Acquisition | China |
| Immunocore | $40 million | The investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV | Bill & Melinda Gates Foundation | Investment | United Kingdom |
| Arcturus Therapeutics | $40 million | Plan to accelerate development of internal programs targeting rare diseases | Alcobra | Merger | United States |
| Immune Therapeutics | $31 million | Agreement Illustrates Immune Therapeutics' Commitment to Providing an Effective and Affordable Non-Toxic Treatment for HIV/AIDS Patients | Omaera Pharmaceuticals | Agreement | United States |
| Disarm Therapeutics | $30 million | Disarm focuses on development treatments for neurological diseases by preventing axonal degeneration | Atlas Venture, with co-investors Lightstone Ventures & AbbVie Ventures | Series A Financing | United States |
| Halozyme Therapeutics | $30 million | ENHANZE® drug-delivery technology | Roche | Collaboration & License Agreement | United States |
| Janssen Pharmaceutica NV & Janssen Sciences Ireland UC | $28 million | Two Clinical-Stage Immunology Assets | Provention Bio | License Agreement | Belgium |
| Rodin Therapeutics | $27 million | The financing announced will fuel the ongoing development of innovative product candidates designed to treat neurological disorders, such as Alzheimer’s disease and Parkinson’s disease. | Atlas Venture, GV (formerly Google Venture), Hatteras Venture Partners, Remeditex Ventures and Third Point Ventures | Financing | United States |
| Integra Holdings | $25 million | Funds will Contribute to Expansion and Development of Integra's Portfolio, Bringing Hebrew University's Life Science Innovations to Market. | Temasek, Arie Capital | Investment | Israel |
| Analytics 4 Life | $25 million | To Advance its Artificial Intelligence-Backed Cardiac Imaging Technology | Undisclosed | Series B Financing | Canada |
| Engage Therapeutics | $23 million | To Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy | TPG Biotech | Series A Financing | United States |
| Eligo Bioscience | $20 million | To take bacteria-killing CRISPR drug into clinic | Khosla Ventures and Seventure Partners | Series A Financing | France |
| Destiny Pharma | $19.8 million | To assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial. | Undisclosed | IPO Funding | United Kingdom |
| Novartis Suffern Partners LLC | $18 million | Resold 162-acre property in Suffern | RS Old Mill | Assets Acquisition | Switzerland |
| XW Laboratories | $17.5 million | Utilize funds to continue the development of its multiple programs that are entering clinical and IND-enabling studies. | Elements Capital and WI Harper (WuXi, Johnson & Johnson) | Series B Financing | China |
| Thermalin | $17.5 million | To develop insulin therapies | Sanofi | Series A Financing & Collaboration | United States |
| Technology Sciences Group | $17 million | The combined operations expand our presence in the global science and technology advisory market | Science Group plc | Acquisition | United States |
| Opexa Therapeutics | $15.7 million | Acer plans to file a NDA for its lead product, EDSIVO™, for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018. | Acer Therapeutics Inc | Merger and Financing | United States |
| Bird & Cronin, Inc. | $15.5 million | Bird & Cronin will be operated following closing of the purchase as a wholly-owned subsidiary of Dynatronics. | Dynatronics Corporation | Acquisition | United States |
| Antidote Technologies | $11 million | To advance it's clinical trial patient matching platform | Merck Global Health Innovation Fund | Fund Raising | United Kingdom |
| Camino Pharma | $10.8 million | Grant for Development of Potential Drug for Cocaine and Nicotine Addiction | National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) | Funding | United States |
| Excision BioTherapeutics | $10 million | To start human testing of its CRISPR-enabled attack on latent HIV virus | Artis Ventures | Seed Funding | United States |
| Landos Biopharma | $10 million | To take a LANCL2-targeted treatment for inflammatory bowel disease (IBD) into the clinic. | Perceptive Advisors | Series A Financing | United States |
| AgeneBio | $10 million | Novel GABAA discovery program to treat mild cognitive impairment due to Alzheimer's disease (MCI due to AD) and delay the onset of Alzheimer’s dementia. | National Institutes of Health (NIH) | Funding | United States |
| DelMar Pharmaceuticals, Inc | $10 million | Registered Direct Offering Priced At-The-Market | Undisclosed | Securities Purchase Agreement | Canada |
| Notable Labs | $10 million | To Advance Personalized Cancer Treatments | Builders VC | Series A Financing | United States |
| Destiny Pharma | $8 million | Signed a binding framework agreement giving CMS the rights to develop and commercialize Destiny's MRSA treatment, XF-73, in Asia | China Medical Systems | Investment | United Kingdom |
| PSR Group | $6.69 million | Orphan drug development | Ergomed | Acquisition | United Kingdom |
| Cellect Biotechnology | $4.3 million | Stem cells selection technology | Undisclosed | Securities Purchase Agreement | Israel |
| BioSensics | $2.5 million | To Develop a Novel Telecare Solution for Huntington’s Disease | National Institutes of Health (NIH) | Funding | United States |
| Imperial College London | $1 million | To Develop Enhanced Surgical Techniques In Sports Medicine | Smith & Nephew | Partnership | United Kingdom |
| Soligenix | $0.7 million | Thermostabilization of an Ebola Vaccine Candidate | UH Manoa and Hawaii Biotech, Inc. | Collaboration/Funding | United States |
| The University Of Queensland Animal Genetics Laboratory | Undisclosed | Animal genomics business | Neogen Corporation | Acquisition | Australia |
| VIB | Undisclosed | Unique Portfolio Of Next-Generation Immuno-Oncology Assets | Oncurious | Acquisition | Belgium |
| Metabolomic Discoveries GmbH | Undisclosed | Acquisition Advances Metabolon’s European Presence and World-Wide Leadership in Metabolomics | Metabolon | Acquisition | Germany |
| Agility Clinical | Undisclosed | Focused specifically on clinical development of rare disease and orphan therapies | Precision For Medicine | Acquisition | United States |
| Trevigen | Undisclosed | As more drug testing is being conducted on physiologically more appropriate cell models | Bio-Techne | Acquisition | United States |
| Vertera Spine | Undisclosed | Implants for spinal fusion using patented porous polyetheretherketone (PEEK) technology | NuVasive | Acquisition | United States |
| Qualyst Transporter Solution | Undisclosed | In vitro hepatic models and services | BioIVT | Acquisition | United States |
| Nexeon Medsystems Belgium, SPRL | Undisclosed | Developing neurostimulation products | Nexeon MedSystems | Acquisition | Belgium |
| University of New Mexico | Undisclosed | Technology To Treat Leukemia A therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukemia | Pascal Biosciences | License Option Agreement | United States |
| OPC Holding Company | Undisclosed | Clinical CRO | TPG Capital Asia | Acquisition | Taiwan |
| Altum Pharmaceuticals | Undisclosed | BiPhasix™ Transdermal Drug Delivery technology | Pivot Pharmaceuticals | Agreement | Canada |
| Alphaeon | Undisclosed | ShoutMD social media platform in its entirety, including all technology and intellectual property rights | Strathspey Crown Holdings | Agreement | United States |
| Rocket Pharma | Undisclosed | Company to Leverage Lentiviral and AAV Gene Therapy Platforms to Target Rare Genetic Diseases | Inotek Pharmaceuticals Corporation | Merger | United States |
| Nuvelution Pharma | Undisclosed | To Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States | Teva Pharmaceutical | Partnership | United States |
| Veniti | Undisclosed | VICI VENOUS STENT® | Boston Scientific | Limited Global Distribution Agreement | United States |
| Phosplatin Therapeutics | Undisclosed | To evaluate PT-112, a novel small molecule inducer of apoptosis with evidence of downstream immunogenic cell death (ICD) properties, currently in Phase I development, in combination with avelumab*, a human anti-PD-L1 IgG1 monoclonal antibody. | Pfizer and Merck KGaA | Collaboration | United States |
| GSK Consumer Healthcare | Undisclosed | This acquisition is an important component of our strategic plan and expands our services by adding additional solid dose capability in the United States | Avara Pharmaceutical Services | Acquisition | United States |
| Bristol-Myers Squibb | Undisclosed | Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors. ABBV-399 to explore the tolerability and potential efficacy of the combination in subjects with advanced c-Met overexpressing NSCLC | AbbVie | Collaboration | United States |
| Inceptua Medicines | Undisclosed | HAEi Global Access Program for RUCONEST | Pharming Group N.V & HAEi International | Limited Global Distribution Agreement | Luxembourg |
| Valensa International | Undisclosed | To Introduce Algae-Sourced Beta-Glucan Ingredients for Immune Health | Kemin | Limited Global Distribution Agreement | United States |
| Eli Lilly | Undisclosed | To create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death. | Geisinger & Boehringer Ingelheim | Collaboration | United States |
| Bristol-Myers Squibb | Undisclosed | Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo | Infinity Pharmaceuticals | Collaboration | United States |
| Boehringer Ingelheim | Undisclosed | Develop New Technology for Monitoring Anti-tumor Activity of the Immune System | ImaginAb Inc | Collaboration | Germany |
| Analytical Biochemical Laboratory | Undisclosed | To Sponsors with botanical & drug discovary | Ardena | Acquisition | Netherlands |
| Simcere | Undisclosed | To Co-Develop And Commercialize Biosimilars In China | Amgen | Collaboration | China |
| BioLineRx | Undisclosed | Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy | Genentech | Collaboration | Israel |
| Foresee Pharmaceuticals | Undisclosed | For the commercialisation in Turkey and certain Middle East countries of Foresee's FP-001 program, LMIS (Leuprolide Mesylate Injectable Suspension) ready-to-use subcutaneous depot formulations. | TRPharm | Limited Global Distribution Agreement | Taiwan |
| UC Berkeley | Undisclosed | To tackle 'undruggable' disease targets | Novartis | Collaboration | United States |
| Shiel Medical Laboratory (Fresenius Medical Care) | Undisclosed | Shiel Medical Laboratory business | Quest Diagnostics | Acquisition | United States |
| Berkeley Lights | Undisclosed | Strategic project to discover antibodies and ramp up the development of cell lines. | Bayer AG | Collaboration | United States |
| Noile-Immune Biotech | Undisclosed | To Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors | Takeda | Collaboration | Japan |
| Breckenridge Pharmaceutical, Inc | Undisclosed | To Commercialize The Generic Version Of A Leading Corticosteroid Product Upon FDA Approval | ImpoPharma | License & Commercialization Agreement | United States |
| Alexza Pharmaceuticals, Inc | Undisclosed | Inhaled Therapy ADASUVE Approved To Treat Agitation Associated With Schizophrenia And Bipolar I Disorder | Galen US Inc | US Commercialization Rights | United States |
| Invicro LLC | Undisclosed | Through molecular digital imaging technology, acquisition offers new value for drug discovery and development focused on the fields of immuno-oncology and neurodegenerative disease. | Konica Minolta, Inc. | Acquisition | United States |
| DePuy Synthes (Johnson & Johnson ) | Undisclosed | Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems | Centinel Spine | Assets Acquisition | United States |
| GE Corporation | Undisclosed | Expands Life Sciences Industry | Cook Group | Agreement | United Kingdom |
| Triple Red | Undisclosed | Efforts to offer a broader range of products and solutions to the research community. | Edstrom Industries | Acquisition | United Kingdom |
| MedVantx | Undisclosed | MedStart Connect Sample Kiosk Program | QPharma, Inc. | Assets Acquisition | United States |
| Imanova | Undisclosed | Combined business delivers world-leading imaging capabilities to drive improved decision-making from early drug discovery to late-phase clinical development | Invicro | Acquisition | United Kingdom |
| Vantage Medical Supplies | Undisclosed | To acquire Vantage Medical Supplies, a major distributor of medical and surgical equipment based in Holtsville, New York. | Dealmed Medical Supplies | Acquisition | United States |
| Medical Imaging Systems | Undisclosed | It will also provide additional leadership to enhance the delivery of imaging equipment to our growing installed base in and around eastern Pennsylvania | Alpha Imaging | Acquisition | United States |
| MERLIN Diagnostika GmbH | Undisclosed | To Add Selected Antibiotic Resistance And Susceptibility Testing To Its MALDI Biotyper Microbial Identification Platform | Bruker Corporation | Acquisition | Germany |
